Close Menu

Interpace Diagnostics

For full-year 2018 the firm's revenues rose 38 percent to $21.9 million from $15.9 million a year ago.

The firm will use the proceeds for working capital, capital payments, business development, research and development payments, and technology and business acquisitions.

The company beat the consensus Wall Street estimate on the top line and guided to 2018 revenues of between $21 million and $22 million.

The firm will begin selling its ThyGeNext thyroid cancer diagnostic tool to physicians in New York and Pennsylvania in combination with ThyraMir.

Priorities for Q3 include the continued buildup of a commercial launch for the company's BarreGEN test. The firm has started a second clinical validation study for the test.

Cigna began covering the company's ThyGeNext next-generation sequencing-based test for thyroid cancer risk assessment in 2017.

The tests have received coverage decisions from a number of Blue Cross Blue Shield plans this year including ones in California and New Jersey.

The company beat the analysts' average estimate on the top line but missed it on the bottom line as it posted a net loss of $3.2 million.

Pages

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

In Science this week: whole-genome sequencing of single sperm cells, and more.